Dynavax Technologies reported $919.71M in Assets for its third fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Assets Change
Adma Biologics ADMA:US $ 238.64M 5.83M
Alexion Pharmaceuticals ALXN:US $ 18650.2M 547.2M
Amgen AMGN:US $ 64993M 5220M
Astrazeneca AZN:US $ 107221M 33580M
AstraZeneca AZN:LN 107221M 33580M
Biogen BIIB:US $ 23806.7M 663.7M
Biomarin Pharmaceutical BMRN:US $ 5977.48M 78.98M
Bristol Myers Squibb BMY:US $ 110893M 96M
Chimerix CMRX:US $ 133.4M 13.32M
Dynavax Technologies DVAX:US $ 919.71M 271.8M
Gilead Sciences GILD:US $ 67098M 886M
Glaxosmithkline GSK:US $ 78689M 1678M
Gw Pharmaceuticals GWPH:US $ 934.34M 5.17M
Idera Pharmaceuticals IDRA:US $ 39.18M 5.23M
Minerva Neurosciences NERV:US $ 97.56M 7.77M
Nektar Therapeutics NKTR:US $ 1277.24M 94.11M
Neurocrine Biosciences NBIX:US $ 2017.3M 60.9M
Novartis NOVN:VX SF 121209M 2806M
Regeneron Pharmaceuticals REGN:US $ 23671.5M 2185.6M
Sarepta Therapeutics SRPT:US $ 2662.22M 96.86M
Tg Therapeutics TGTX:US $ 409.69M 71.71M
Vertex Pharmaceuticals VRTX:US $ 12618.74M 397.06M